A Phase 1/1b clinical trial designed to confirm the dose and evaluate the safety, pharmacokinetics, immune biomarkers, and efficacy as a single agent, and in combination with pembrolizumab

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 10 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Mupadolimab (Primary) ; Pembrolizumab (Primary)
Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions

06 May 2024 According to Corvus Pharmaceuticals media release, Angel Pharmaceuticals, Corvus partner in China, is enrolling patients in this trial.
06 May 2024 Status changed from planning to recruiting, according to a Corvus Pharmaceuticals media release.
26 Sep 2022 According to an Angel Pharmaceuticals media release, IND application to initiate a Phase 1/1b clinical trial of mupadolimab has been approved by the Center for Drug Evaluation of the China National Medical Products Administration.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com